English
Spanishwelcome to oneGRAVESvoice
- a positively charged Graves' disease and thyroid eye disease community.- join today!
- log in
Teprotumumab Improves Short and Long-Term Clinical Outcomes in Thyroid Eye Disease
Most adults with thyroid eye disease receiving an infusion of teprotumumab every 3 weeks for a 24-week period had a reduction of at least 2 mm in proptosis, with a long-term response observed in 67% of participants, according to study data.
“These analyses provide insight into both the short-term and long-term efficacy and safety of teprotumumab and are clinically relevant as all objective signs and symptoms of thyroid eye disease, especially proptosis and diplopia, which can be resistant to medical therapy, were markedly and significantly improved with teprotumumab,” George J. Kahaly, MD, PhD, a professor of medicine, endocrinology and metabolism at Johannes Gutenberg University Medical Center in Mainz, Germany, and colleagues wrote in a study published in The Lancet Diabetes & Endocrinology.
rareRelated
-
TEPEZZA Has Resumed Production – FAQHorizon Therapeutics, the developer of T...
-
Management of Graves Thyroidal and Extrathyroidal Disease: An UpdateContext: Invited update on the manageme...
-
Eyes on Graves’: LaQuilla’s Storyhttps://www.youtube.com/watch?v=98tJEN1C...
-
Association of T and B Cells Infiltrating Orbital Tissues With Clinical Features of Graves’ OrbitopathyImportance: Graves orbitopathy (GO) res...
-
FDA Approves First Treatment for Thyroid Eye Disease (Teprotumumab)The U.S. Food and Drug Administration (F...
-
Prem Subramanian, MD, PhDPrem S. Subramanian is the Professor of ...
-
Jack Ronald Wall, PhDJack Ronald Wall is a Professor of Medic...
